Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:IGMS NASDAQ:MDGL NASDAQ:NGM NASDAQ:RVNC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$17.32-0.1%$12.91$7.08▼$17.49$358.85M0.8282,842 shs96,115 shsIGMSIGM Biosciences$1.36+0.7%$1.23$0.92▼$22.50$80.70M0.48379,737 shs394,761 shsMDGLMadrigal Pharmaceuticals$314.64+2.0%$288.60$200.63▼$377.46$6.85B-1.05357,817 shs188,614 shsNGMNGM Biopharmaceuticals$1.54$1.55$0.60▼$4.69$128.53M1.271.47 million shsN/ARVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.69 million shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.06%+6.95%+35.10%+86.24%+14.17%IGMSIGM Biosciences+0.74%+0.37%+0.74%+13.33%-80.60%MDGLMadrigal Pharmaceuticals+1.96%+5.41%+11.45%-0.79%+10.64%NGMNGM Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%+25.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.7447 of 5 stars0.55.00.00.02.60.00.6IGMSIGM Biosciences4.4854 of 5 stars3.04.00.04.62.33.30.6MDGLMadrigal Pharmaceuticals4.1617 of 5 stars3.40.00.04.62.63.30.6NGMNGM Biopharmaceuticals1.7462 of 5 stars0.00.00.04.70.03.31.3RVNCRevance Therapeutics2.8006 of 5 stars3.10.00.04.70.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.00Sell$12.00-30.72% DownsideIGMSIGM Biosciences 1.90Reduce$5.50304.41% UpsideMDGLMadrigal Pharmaceuticals 2.89Moderate Buy$420.6333.68% UpsideNGMNGM Biopharmaceuticals 0.00N/AN/AN/ARVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideCurrent Analyst Ratings BreakdownLatest NGM, IGMS, RVNC, AMRN, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$7.00 ➝ $12.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/24/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.57N/AN/A$23.62 per share0.73IGMSIGM Biosciences$2.68M30.34N/AN/A$0.82 per share1.66MDGLMadrigal Pharmaceuticals$180.13M38.78N/AN/A$34.59 per share9.10NGMNGM Biopharmaceuticals$4.42M29.10N/AN/A$1.80 per share0.86RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)IGMSIGM Biosciences-$195.79M-$3.27N/AN/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)NGMNGM Biopharmaceuticals-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/ARVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)Latest NGM, IGMS, RVNC, AMRN, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.64N/AN/AN/A$158.94 millionN/A7/30/2025Q2 2025AMRNAmarin-$0.60N/AN/AN/A$45.45 millionN/A5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ANGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.532.55IGMSIGM BiosciencesN/A5.715.71MDGLMadrigal Pharmaceuticals0.175.915.58NGMNGM BiopharmaceuticalsN/A7.797.79RVNCRevance TherapeuticsN/A4.123.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%IGMSIGM Biosciences42.79%MDGLMadrigal Pharmaceuticals98.50%NGMNGM Biopharmaceuticals75.74%RVNCRevance Therapeutics97.70%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%IGMSIGM Biosciences57.00%MDGLMadrigal Pharmaceuticals21.50%NGMNGM Biopharmaceuticals35.90%RVNCRevance Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million20.02 millionOptionableIGMSIGM Biosciences19059.78 million25.70 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableNGMNGM Biopharmaceuticals13883.46 million53.50 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableNGM, IGMS, RVNC, AMRN, and MDGL HeadlinesRecent News About These CompaniesRevance Names New CEO to Drive Next Phase in Aesthetic InnovationMay 23, 2025 | globalcosmeticsnews.comGRevance Announces Leadership Succession Plan to Support Next Phase of Growth and InnovationMay 21, 2025 | finance.yahoo.comCrown Laboratories Now Operates Under the Name RevanceMarch 31, 2025 | finance.yahoo.comJohnson City-based Crown Labs now operating as ‘Revance’March 31, 2025 | wjhl.comWREVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMarch 6, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & KorsinskyMarch 4, 2025 | accessnewswire.comALevi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNCMarch 4, 2025 | accessnewswire.comARVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 4, 2025 | accessnewswire.comAContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | globenewswire.comContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | accessnewswire.comARevance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCMarch 4, 2025 | accessnewswire.comAFINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action LawsuitMarch 4, 2025 | accessnewswire.comAInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 4, 2025 | prnewswire.comInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 3, 2025 | accessnewswire.comAMarch 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCMarch 3, 2025 | accessnewswire.comARVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 3, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 3, 2025 | accessnewswire.comADeadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMarch 3, 2025 | businesswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNCMarch 3, 2025 | globenewswire.comLevi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming DeadlineMarch 3, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeNGM, IGMS, RVNC, AMRN, and MDGL Company DescriptionsAmarin NASDAQ:AMRN$17.32 -0.01 (-0.06%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$17.34 +0.02 (+0.09%) As of 07/10/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.IGM Biosciences NASDAQ:IGMS$1.36 +0.01 (+0.74%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.35 -0.01 (-0.74%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Madrigal Pharmaceuticals NASDAQ:MDGL$314.64 +6.05 (+1.96%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$315.23 +0.59 (+0.19%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.NGM Biopharmaceuticals NASDAQ:NGMNGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Revance Therapeutics NASDAQ:RVNC$3.65 0.00 (0.00%) As of 02/6/2025Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
